These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34587546)

  • 1. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.
    Li NX; Hu YR; Chen WN; Zhang B
    J Affect Disord; 2022 Jan; 296():26-34. PubMed ID: 34587546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis.
    Hsu TW; Stubbs B; Liang CS; Chen TY; Yeh TC; Pan CC; Chu CS
    Ageing Res Rev; 2021 Aug; 69():101362. PubMed ID: 34000464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
    Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS
    CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
    Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
    Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis.
    Dauwan M; Begemann MJ; Heringa SM; Sommer IE
    Schizophr Bull; 2016 May; 42(3):588-99. PubMed ID: 26547223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
    Goldberg SB; Pace BT; Nicholas CR; Raison CL; Hutson PR
    Psychiatry Res; 2020 Feb; 284():112749. PubMed ID: 31931272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Resistance Training Interventions on 'The Self' in Youth: a Systematic Review and Meta-analysis.
    Collins H; Booth JN; Duncan A; Fawkner S; Niven A
    Sports Med Open; 2019 Jul; 5(1):29. PubMed ID: 31270635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials.
    Giacobbe P; Rakita U; Lam R; Milev R; Kennedy SH; McIntyre RS
    J Affect Disord; 2018 Jan; 226():294-300. PubMed ID: 29028590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.
    Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS
    Psychiatry Res; 2022 Jul; 313():114577. PubMed ID: 35580433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Lavender on Anxiety, Depression, and Physiological Parameters: Systematic Review and Meta-Analysis.
    Kim M; Nam ES; Lee Y; Kang HJ
    Asian Nurs Res (Korean Soc Nurs Sci); 2021 Dec; 15(5):279-290. PubMed ID: 34775136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials.
    Hsu TW; Chu CS; Ching PY; Chen GW; Pan CC
    J Affect Disord; 2022 Jun; 306():182-189. PubMed ID: 35331821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.